Published in J Clin Neurol on March 31, 2011
Sex differences in cognitive impairment and Alzheimer's disease. Front Neuroendocrinol (2014) 1.08
Mechanisms underlying insulin deficiency-induced acceleration of β-amyloidosis in a mouse model of Alzheimer's disease. PLoS One (2012) 0.94
Metabolic Risk Factors of Sporadic Alzheimer's Disease: Implications in the Pathology, Pathogenesis and Treatment. Aging Dis (2015) 0.90
Insulin resistance in Alzheimer's disease. Neurobiol Dis (2014) 0.88
Kisspeptin prevention of amyloid-β peptide neurotoxicity in vitro. ACS Chem Neurosci (2012) 0.83
Obesity and diabetes cause cognitive dysfunction in the absence of accelerated β-amyloid deposition in a novel murine model of mixed or vascular dementia. Acta Neuropathol Commun (2014) 0.82
Elevated glucose and oligomeric β-amyloid disrupt synapses via a common pathway of aberrant protein S-nitrosylation. Nat Commun (2016) 0.80
Molecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisal. World J Diabetes (2015) 0.80
Magnesium protects cognitive functions and synaptic plasticity in streptozotocin-induced sporadic Alzheimer's model. PLoS One (2014) 0.78
Tau phosphorylation and μ-calpain activation mediate the dexamethasone-induced inhibition on the insulin-stimulated Akt phosphorylation. PLoS One (2012) 0.78
Human gut microbiota: the links with dementia development. Protein Cell (2016) 0.77
Amelioration of Metabolic Syndrome-Associated Cognitive Impairments in Mice via a Reduction in Dietary Fat Content or Infusion of Non-Diabetic Plasma. EBioMedicine (2015) 0.77
Neuroinflammation is not a Prerequisite for Diabetes-induced Tau Phosphorylation. Front Neurosci (2015) 0.76
Role of anti-diabetic drugs as therapeutic agents in Alzheimer's disease. EXCLI J (2015) 0.75
The Association of Type 2 Diabetes Mellitus with Cerebral Gray Matter Volume Is Independent of Retinal Vascular Architecture and Retinopathy. J Diabetes Res (2016) 0.75
Glucagon-Like Peptide-1 (GLP-1) Treatment Ameliorates Cognitive Impairment by Attenuating Arc Expression in Type 2 Diabetic Rats. Med Sci Monit (2017) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology (1999) 7.55
RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature (1996) 7.04
The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res (2001) 6.59
Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med (2006) 6.15
Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A (2003) 5.44
Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol (2004) 5.11
GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature (2003) 4.97
Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes (2002) 4.97
Alzheimer's disease: clinical trials and drug development. Lancet Neurol (2010) 4.65
Advanced protein glycosylation in diabetes and aging. Annu Rev Med (1995) 4.13
Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron (2003) 4.11
Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? J Alzheimers Dis (2005) 3.78
Caspase activation precedes and leads to tangles. Nature (2010) 3.24
The GSK3 hypothesis of Alzheimer's disease. J Neurochem (2007) 3.16
Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat Neurosci (2008) 3.11
Increased risk of type 2 diabetes in Alzheimer disease. Diabetes (2004) 2.61
Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology (1998) 2.61
Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol (1997) 2.60
Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J (2004) 2.56
Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A (2004) 2.54
Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A (2009) 2.50
Insulin increases CSF Abeta42 levels in normal older adults. Neurology (2003) 2.27
Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J (2007) 2.25
Magnetic resonance imaging of the brain in diabetes: the Cardiovascular Determinants of Dementia (CASCADE) Study. Diabetes (2004) 2.17
Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis (2005) 2.12
Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet (1999) 2.11
Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology (2004) 2.10
Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A (1994) 2.09
Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am J Psychiatry (2006) 2.05
Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci (2003) 2.03
Basal cortisol levels and cognitive deficits in human aging. J Neurosci (1994) 1.97
Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A (2010) 1.97
Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem (2007) 1.95
Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol (2001) 1.74
Recent developments in Alzheimer's disease therapeutics. BMC Med (2009) 1.63
Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci (2007) 1.58
Neurocognitive correlates of type 1 diabetes mellitus in childhood. Child Neuropsychol (2004) 1.58
Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J Neurosci Res (2008) 1.50
Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes (2007) 1.48
Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain (2009) 1.48
Type 2 diabetes and cognitive function in community-dwelling elderly women. Diabetes Care (2001) 1.48
The insulin/Akt signaling pathway is targeted by intracellular beta-amyloid. Mol Biol Cell (2009) 1.45
Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol (2003) 1.44
Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology (2009) 1.39
GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis (2010) 1.36
Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol (2005) 1.33
Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochem Biophys Res Commun (2009) 1.28
Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro. J Biol Chem (2004) 1.27
High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model. Neurobiol Aging (2008) 1.26
Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS One (2009) 1.23
Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway. J Neurochem (2006) 1.23
Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease. Am J Pathol (2009) 1.21
Differential effects of proteases involved in intracellular degradation of amyloid beta-protein between detergent-soluble and -insoluble pools in CHO-695 cells. Biochemistry (2002) 1.13
Plasma insulin, growth hormone, cortisol, and central obesity among young Chinese type 2 diabetic patients. Diabetes Care (1999) 1.11
Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice. J Alzheimers Dis (2010) 1.07
Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies. J Clin Neurol (2009) 1.06
Immunological analysis of glucose transporters expressed in different regions of the rat brain and central nervous system. Biochem Biophys Res Commun (1993) 1.04
Elevated basal cortisol level predicts lower hippocampal volume and cognitive decline in Alzheimer's disease. J Clin Neurosci (2009) 1.03
Increased food intake leads to obesity and insulin resistance in the tg2576 Alzheimer's disease mouse model. Endocrinology (2010) 0.93
Age-dependent changes in phenotypes and candidate gene analysis in a polygenic animal model of Type II diabetes mellitus; NSY mouse. Diabetologia (2000) 0.93
The economic costs of dementia in Korea, 2002. Int J Geriatr Psychiatry (2006) 0.81